---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-119245"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2024-10-31T23:59:59+00:00"
generated_at: "2026-05-30T07:37:05.834247+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Kymera posts Q3 net loss $62.5M; initiates STAT6 degrader Phase 1; shifts focus to immunology

## Summary
- Net loss $62.5M in Q3 2024 vs $52.9M in Q3 2023; collaboration revenue $3.7M from Sanofi.
- Initiated Phase 1 dosing for KT-621 (STAT6 degrader); Phase 1 data expected H1 2025.
- Sanofi expands KT-474 (IRAK4) Phase 2 HS/AD trials to dose-ranging Phase 2b; primary completion mid-2026.
- Selected KT-295 (TYK2 degrader) as development candidate; Phase 1 start in H1 2025.
- Cash $911M as of Sep 30, 2024; runway into mid-2027; will only advance oncology with partner.

## SEC filing metadata
- accession: 0000950170-24-119245
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2024-10-31T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000095017024119245/0000950170-24-119245-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000095017024119245/kymr-20241031.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-119245
- JSON: https://secwatch.observer/filing/0000950170-24-119245.json
- Plain text: https://secwatch.observer/filing/0000950170-24-119245.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.